Overexpression of GCC2-ALK has been shown to activate downstream ALK signaling that can be inhibited by ALK inhibitors including crizotinib and ceritinib; therefore, the direct involvement of GCC2 makes it a promising target for NSCLC diagnosis and/or treatment [28]. This evidence concerns the gene GCC2 and non-small cell lung carcinoma.